Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Kavanaugh

Showing results (21-30 of 158) with videos related to

Pageof 16
Sort By:
Clinical and Experimental Rheumatology|November 4, 2010
Use of methotrexate in patients with psoriatic arthritisA Ceponis, A Kavanaugh
Annals of the Rheumatic Diseases|October 30, 2003
Cigarette smoking, TB, and TNF inhibitorsJ Bieber, A Kavanaugh
Clinical and Experimental Rheumatology|November 24, 2004
Tuberculosis and opportunistic infections: relevance to biologic agentsJ Bieber, A Kavanaugh
Annals of Internal Medicine|January 1, 1996
Folic acid and methotrexate in rheumatoid arthritisA Kavanaugh, D Kavanaugh
Clinical and Experimental Rheumatology|November 7, 2006
Defining remission in psoriatic arthritisA Kavanaugh, J Fransen
Clinical and Experimental Rheumatology|November 9, 2005
The assessment of disease activity and outcomes in psoriatic arthritisA Kavanaugh, S Cassell
Annals of the Rheumatic Diseases|November 18, 2004
A need for greater reporting of socioeconomic status and race in clinical trialsS J Lee, A Kavanaugh
Rheumatology (Oxford, England)|January 26, 2000
The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapiesP E Lipsky, A Kavanaugh
International Journal of Dermatology|April 1, 1990
HTLV-ID J Gross, A Kavanaugh
Clinical and Experimental Rheumatology|February 19, 2004
The safety of biologic agents in early rheumatoid arthritisA Kavanaugh, E C Keystone
Pageof 16

Showing results (21-30 of 158) with videos related to

Sort By:
Pageof 16
Clinical and Experimental Rheumatology|November 4, 2010
Use of methotrexate in patients with psoriatic arthritisA Ceponis, A Kavanaugh
Annals of the Rheumatic Diseases|October 30, 2003
Cigarette smoking, TB, and TNF inhibitorsJ Bieber, A Kavanaugh
Clinical and Experimental Rheumatology|November 24, 2004
Tuberculosis and opportunistic infections: relevance to biologic agentsJ Bieber, A Kavanaugh
Annals of Internal Medicine|January 1, 1996
Folic acid and methotrexate in rheumatoid arthritisA Kavanaugh, D Kavanaugh
Clinical and Experimental Rheumatology|November 7, 2006
Defining remission in psoriatic arthritisA Kavanaugh, J Fransen
Clinical and Experimental Rheumatology|November 9, 2005
The assessment of disease activity and outcomes in psoriatic arthritisA Kavanaugh, S Cassell
Annals of the Rheumatic Diseases|November 18, 2004
A need for greater reporting of socioeconomic status and race in clinical trialsS J Lee, A Kavanaugh
Rheumatology (Oxford, England)|January 26, 2000
The impact of pharmaco-economic considerations on the utilization of novel anti-rheumatic therapiesP E Lipsky, A Kavanaugh
International Journal of Dermatology|April 1, 1990
HTLV-ID J Gross, A Kavanaugh
Clinical and Experimental Rheumatology|February 19, 2004
The safety of biologic agents in early rheumatoid arthritisA Kavanaugh, E C Keystone
Pageof 16